Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · IEX Real-Time Price · USD
1.740
+0.010 (0.58%)
At close: Jul 19, 2024, 4:00 PM
1.760
+0.020 (1.15%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Plus Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Plus Therapeutics stock has a target of 8.00, which predicts an increase of 359.77% from the current stock price of 1.74.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 15, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for PSTV is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '23 | Apr '23 | May '23 | Jun '23 | Jul '23 | Aug '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +359.77% | Aug 15, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +359.77% | Aug 14, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3.5 → $8 | Strong Buy | Maintains | $3.5 → $8 | +359.77% | Jun 30, 2023 |
| Maxim Group | Maxim Group | Strong Buy Maintains $30 → $12 | Strong Buy | Maintains | $30 → $12 | +589.66% | May 3, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +2,917.24% | Apr 21, 2023 |
Financial Forecast
Revenue This Year
5.17M
from 4.91M
Increased by 5.21%
Revenue Next Year
4.39M
from 5.17M
Decreased by -15.15%
EPS This Year
-2.12
from -4.24
EPS Next Year
-2.35
from -2.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 7.3M | 5.3M | n/a | 57.0M | 92.4M |
| Avg | 5.2M | 4.4M | n/a | 27.7M | 89.4M |
| Low | 1.6M | 3.5M | n/a | n/a | 85.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 48.0% | 1.6% | - | - | 233.4% |
| Avg | 5.2% | -15.1% | - | - | 222.6% |
| Low | -66.6% | -31.7% | - | - | 208.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.77 | -1.69 | -1.25 | -0.14 | 0.93 |
| Avg | -2.12 | -2.35 | -2.70 | -1.90 | 0.70 |
| Low | -2.52 | -3.51 | -4.03 | -3.52 | 0.47 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.